Table 2 Demographic data of pneumocystis-infected (PcP (+)) and pneumocystis-free (PcP (−)) patients in the rituximab group.
From: Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
Rituximab group | |||
|---|---|---|---|
PcP (+) N = 223 (100%) | PcP (−) N = 7331 (100%) | p value | |
Age (y) | 59.4 ± 14.7 | 61.1 ± 16.1 | 0.14 |
Gender ratio | <0.0001 | ||
Male | 150 (67.2%) | 3988 (54.4%) | |
Female | 73 (32.7%) | 3343 (45.6%) | |
Chronic pulmonary disease | 67 (30.0%) | 2557 (34.8%) | 0.13 |
Rheumatologic diseases | 50 (22.4%) | 1799 (24.5%) | 0.46 |
Diabetes mellitus (DM) | 41 (18.3%) | 1653 (22.5%) | 0.14 |
DM with chronic complications | 11 (4.9%) | 444 (6.0%) | 0.48 |
Chronic kidney disease | 50 (22.4%) | 1799 (24.5%) | 0.46 |
